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ABSTRACT
The purpose of this study was to estimate treatment cost for typhoid fever at two hospitals in Kolkata, 
India. This study was an incidence-based cost-of-illness analysis from the providers’ perspective. Micro-
costing approach was employed for calculating patient-specific data. Unit costs of medical services used in 
the calculation were directly measured from the study hospital by standard method. The study hospitals 
were selected based on accessibility to data and cooperation. Eighty-three Widal-positive and/or culture-
confirmed patients with typhoid fever during November 2003–April 2006 were included in the study. Most 
(93%) patients were children. Eighty-one percent was treated at the outpatient department. The average 
duration of hospitalization for child and adult patients was 8.4 and 4.2 days respectively. The average cost 
of treating children, adults, and all patients was US$ 16.72, 72.71, and 20.77 respectively (in 2004 prices). 
Recalculation based on 80% occupancy rate in inpatient wards (following the recommendation of the 
World Health Organization) found that the cost of treating children, adults, and all patients was US$ 14.53, 
36.44, and 16.11 respectively.                                                                                                                
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INTRODUCTION
Typhoid fever has been an important health prob-
lem in many parts of the world.  It is estimated that 
16 million cases and 600,000 deaths occur each year 
(1). The typhoid vaccines have been introduced in 
many countries including India (2). In India, the 
cost of illness from typhoid fever and vaccine-eval-
uation studies were also conducted in 1996 in New 
Delhi (3,4). However, India is a vast country, and 
the states are very big and are quite different in en-
vironment and health service patterns. Hence, re-
sults of studies in one state may not be sufficient to 
be generalized for different states and for the whole 
country. The present study was an attempt to esti-
mate the cost of illness from typhoid fever at two 
hospitals in Kolkata.
Kolkata, a district of the state of West Bengal, has 
an area of approximately 185 sq km and had a total 
population of 4,572,876 in 2001 (Census of India 
2001).  The urban area has an estimated population-
density of 24,718 persons per sq km. About 32.5% 
of the total population in Kolkata lives in slum ar-
eas (Census of India 2001). Typhoid fever, charac-
terized by high fever, chills, headache, and malaise 
or delirium, is one of the health problems in West 
Bengal, especially in the overcrowded slums in Kol-
kata. A surveillance based on two urban slums of 
Kolkata conducted during November 2003–Octo-
ber 2004 found that the incidence of typhoid fever 
per 1,000 per year was 0.9 for children aged less than 
two years, 3.4 for the age-group of 2-4.99 years, 4.9 
for the age-group of 5-14.99 years, and 1.2 for the 
age group of 15 years and above (5). Lack of proper 
sanitation, safe drinking-water, hygienic practices, 
and health education results in high prevalence of 
this disease among slum dwellers. Although im-
provements in water and sanitation infrastructure 
and food-hygiene could reduce the burden of dis-
ease and lessen the threat of antibiotic resistance, 
another strategy to reduce typhoid cases in the near 
term is vaccination with new-generation vaccines 
(6). To introduce a vaccine to the health service 
system, the burden of disease, including economic 
consequences, must be explored to determine prio-
rity. In addition, information on economic burden Sur D et al. Treatment cost for typhoid fever
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or cost of illness is important in the evaluation of 
vaccination programmes. Costs of illness can be 
estimated from private and public points of view. 
Private cost of illness focuses on the treatment cost 
borne by the patients themselves or the caregivers 
(in the case of child patients) while public cost of 
illness estimates the total cost incurred by a health-
care provider to treat a particular patient, i.e. the 
public cost-of-illness study provides estimates from 
the perspective of the healthcare system. The pres-
ent study was a public cost-of-illness study aimed 
at estimating treatment cost for typhoid fever at 
two hospitals in Kolkata, viz. the B C Roy Memorial 
Hospital for Children and the Infectious Diseases & 
Beliaghata General Hospital. 
MATERIALS AND METHODS
Cost-of-illness studies use either a prevalence-
based or incidence-based approach, depending on 
whether a fixed-time horizon or life-time horizon 
is adopted as the conceptual paradigm (7). The 
prevalence-based cost-of-illness studies measure the 
economic burden of a disease in a given period. In 
contrast, the incidence-based approach measures 
the economic burden from the onset of disease 
until cure or death. It observes only new cases oc-
curring in a given period and monitors until the 
end-point is reached. Hence, in the present study, 
the incidence-based approach was used. This study 
was analyzed from the provider’s perspective (7). 
To select the study site, retrospective surveys on 
hospital data were carried out during 2002-2003 in 
two hospitals in Kolkata—the Infectious Diseases & 
Beliaghata General Hospital and the B C Roy Me-
morial Hospital for Children. These two hospitals 
were selected based on accessibility to data and 
cooperation. The survey results showed that most 
patients with enteric diseases admitted or treated 
as outpatients at these two hospitals were from 
two Kolkata municipal wards, viz. Ward 29 and 30. 
Hence, these two wards were selected for the pres-
ent study. Ward 29 and 30 are very congested ur-
ban slums capturing an area of about 0.7 sq km and 
have a total population of 75,165.
The B C Roy Memorial Hospital for Children is a 
teaching hospital specializing in paediatric medi-
cine; it has approximately 250 beds, 51 doctors, 
90 nurses, 20 supporting staff (pathologist, phys-
iotherapist, etc.), 26 administrative staff, and 125 
Group D staff (sweeper, peon, etc.). The hospital 
provides both inpatient and outpatient care. On 
an average, 500 patients are treated as outpatients 
daily. The Infectious Diseases & Beliaghata General 
Hospital has 560 beds. Most common infectious 
diseases treated in this hospital are diarrhoea, diph-
theria, whooping cough, tetanus (including neona-
tal tetanus), rabies, encephalitis, complicated cases 
of measles and chicken pox, and a few other infec-
tious diseases. The hospital also has an outpatients 
department where approximately 150 patients are 
seen daily. In total, 62 doctors take care of these pa-
tients with the help of 157 nurses, 21 paramedical 
staff, and 252 Group D staff.
Treating patients with typhoid fever is a part of 
the hospital services. Based on routine practice, 
patients are clinically diagnosed and treated by the 
hospital doctors. However, for some patients, labo-
ratory investigations are performed for confirma-
tion. For example, Widal test is often performed by 
the hospital for patients with typhoid fever. All ty-
phoid-positive cases (Widal-positive, i.e. TO (titre of 
antibody developed against ‘O’ antigen of typhoid 
causing bacteria) ≥80 or culture-confirmed) admit-
ted or treated as outpatients at the B C Roy 
Memorial Hospital for Children and at the Infec-
tious Diseases & Beliaghata General Hospital from 
Ward 29 and 30 during November 2003–April 2006 
were included in the present study. In total, 83 
cases were included. These patients were identified 
from the ongoing passive surveillance of the Dis-
eases of Most Impoverished (DOMI) programme 
in these two wards. The DOMI programme, ad-
ministered by the International Vaccine Institute, 
Seoul, South Korea, involved a number of paral-
lel activities, such as epidemiological studies, eco-
nomic studies, and investigation of the feasibility 
of vaccine-technology transfer in several Asian 
countries, including India. Surveillance was a ma-
jor part of the whole study, and results of the sur-
veillance showed that, during the present study 
period, the total number of typhoid-positive cases 
was 2,658, of which 2,285 were widal-positive cases 
(TO ≥80)  and 373 were culture-confirmed cases. As 
part of the DOMI programme, five health outposts 
were set up in ward 29 and 30 and one each at the 
Infectious Diseases & Beliaghata General Hospital 
and B C Roy Memorial Hospital for Children. In 
addition to passive surveillance, the communi-
ty health workers visited each household in the 
study areas on a monthly basis to encourage fe-
brile patients to attend those participating health-
care facilities. The private practitioners around 
the study areas were also encouraged to refer pa-
tients for diagnosis and treatment free of charge 
at those facilities (5). As a result, patients from the 
study area with symptoms of typhoid fever were 
diagnosed and treated at the local healthcare facili-
ties at a very early stage of the disease, and the dis-
ease did not become severe. This was evident from 
the results of the surveillance which showed that 
only 2% of typhoid cases required hospitaliza-Sur D et al. Treatment cost for typhoid fever
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tion, and all detected cases were recovered, and no 
death due to typhoid was reported during Novem-
ber 2003–October 2004 (5). Clearly, because of this 
intervention, only a few patients were admitted 
or treated as outpatients at the study hospitals, al-
though there were substantial numbers of typhoid-
positive cases.
For this study, resources used by the hospitals and 
service outputs were collected from the official 
records of the two hospitals. The hospital-related 
data were collected for the 2004-2005 financial 
year. Hence, the cost calculation of this study was 
based on the 2004 prices. The clinical status and 
the treatment provided to each patient were col-
lected from the ongoing surveillance programme 
in the two wards.
Cost-of-illness is composed of direct medical, non-
medical, and indirect costs (7). However, as results 
of the present study were analyzed from the pro-
vider’s perspective, it covered only the provider’s 
cost, i.e. direct medical cost. Direct medical cost is 
healthcare-related costs directly spent for the pre-
vention, detection,  treatment,  continuing  care, 
rehabilitation,  and  terminal  care  of  patients  (7). 
Direct medical cost was calculated by multiplying 
the quantity of medical services consumed by their 
unit costs. A micro-costing bottom-up approach 
was used for calculating the unit cost of medical 
services (Fig. 1) (8). The calculation was composed 
of five steps: organization analysis and cost centre 
classification, determination of direct cost, deter-
mination of indirect cost, determination of full 
cost, and calculating unit cost of medical services 
(Fig. 2). 
At first, all departments of the hospital were clas-
sified into patient-care cost centres and support-
ing cost centres. The direct cost of each cost centre 
was calculated by summing up its labour, material 
and capital costs. Labour cost was the summation 
of salaries, overtime pay, and other fringe benefits, 
such as healthcare expenses, travel allowance, etc. 
Material costs included costs of maintenance, elec-
tricity, telephone, petrol, meals, security, and mis-
cellaneous expenses. For limitation to access data 
of capital assets, capital cost was estimated at 15% 
of the total cost. This was an approximate average 
proportion from reports in Thailand: 17.8% in a 
60-bed hospital (9), 15.89% in a 509-bed hospital 
(10), 11% in a 30-bed hospital (11).
After deriving the direct cost of all the cost centres, 
the direct costs of the supporting cost centres were 
allocated to patient-care cost centres by employing 
simultaneous equation method (12). The direct 
costs of the supporting cost centres, after being allo-
cated to the patient-care cost centres, were termed 
as indirect cost of the patient-care cost centres. Full 
cost of each patient-care cost centre was obtained 
by adding up direct and indirect costs. 
For the calculation of unit cost, the departments 
producing homogeneous products, such as phar-
macy, outpatient department, and inpatient de-
partment, average method was used (13,14). For 
example, to get the unit cost per outpatient visit, 
full cost of the outpatient department was divided 
by the total number of outpatient visits at the hos-
pital during the whole year. However, to calculate 
the unit cost of services produced at the pathology 
department (heterogeneous output), ratio of costs 
to charges (RCC) method was used (13,14). RCC 
is computed when the information on the full 
cost of the department, prices, and total number 
of services produced is available. In this calcula-
tion process, total expected charge was calculated 
first by multiplying unit prices of services and total 
number of services produced. Then, full cost of the 
department was divided by total expected charge 
resulting in the ratio of cost to charge. Finally, that 
ratio was used for multiplying unit price, resulting 
in unit cost of each service. 
The final step was to calculate treatment cost of 
an individual patient. As part of the surveillance 
programme of the DOMI project, a clinical record 
form was designed to record service-use by each pa-
tient. Drugs and their quantities used by each pa-
tient were drawn from the clinical record form and 
then multiplied by drug-prices to retailer from the 
Drug Today (15), resulting in acquisition drug cost. 
Dispensing cost was added to acquisition drug cost, 
resulting in gross pharmacy cost. The numbers of 
outpatient visits, hospitalization days, and labora-
tory tests were multiplied by their unit costs. Total 
treatment cost was obtained by adding up all these 
costs. The present study was based on the assump-
tion of real-life practice. Hence, the laboratory tests, 
e.g. Widal test or culture done for the confirmation 
of the pathogen for the research purpose, were not 
included in the calculation of cost. This was consis-
tent with the exclusion criteria mentioned in the 
guidelines for economic evaluations in pharmaceu-
ticals (16). However, costs of laboratory tests that 
were parts of treatment were included. All costs 
were presented in US dollar at the 2004 prices.  
Hence, types of cost for this study were the follow-
ing:
a. Laboratory cost consisting of practical labora-
tory investigations—the test used for research 
purpose—was not included.Sur D et al. Treatment cost for typhoid fever
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b. Pharmacy cost equalled acquisition drug cost 
plus drug-dispensing cost  
c. Routine service cost was the sum of outpatient 
and inpatient service.
d. Total cost or total treatment cost consisting of all 
costs mentioned above (points a, b, and c).
RESULTS
The results were presented as outpatient and in-
patient treatment costs. The patients were classi-
fied as children (aged less than 18 years) and 
adults (aged 18 years or more). Descriptive statistics 
were employed in the analysis. Based on available 
data, the Infectious Diseases & Beliaghata General 
Hospital and the B C Roy Memorial Hospital for 
Children had 34% and 75% occupancy rates of 
hospitalization services respectively. Following the 
recommendation of the World Health Organiza-
tion, sensitivity analysis was conducted at 80% of 
capacity-use (17).  
Unit cost of medical services was calculated for es-
timating treatment cost. Two study hospitals had 
different levels of capacity-use. Inpatient-bed occu-
pancy rate of the B C Roy Memorial Hospital for 
Children was two times higher than that of the 
Fig. 2. Steps of unit cost calculation
Classiﬁcation of hospital departments 
Supporting cost centres  Patient-care cost centres 
Direct cost determination  Direct cost determination 
Cost allocated to patient-care cost centres 
Indirect cost of patient-care cost centres 
Sum of direct and indirect cost of patient-
care cost centres 
Full cost of patient-care cost centres 
Unit cost of medical services at patient- 
care cost centres 
Fig. 1. Conceptual framework of the micro-costing approach
Administrative/Supportive Departments
IPD=Inpatient department; OPD=Outpatient department 
Average treatment cost
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Infectious Diseases & Beliaghata General Hospital 
(75% and 34% respectively). Costs per inpatient 
day were US$ 10.80 and US$ 15.27 for the B C Roy 
Memorial Hospital for Children and the Infectious 
Diseases & Beliaghata General Hospital respective-
ly. In contrast, outpatient routine service (or con-
sultation) costs were US$ 0.69 and US$ 0.37 for the 
B C Roy Memorial Hospital for Children and the 
Infectious Diseases & Beliaghata General Hospital 
respectively (Table 1).
Output
Infectious Diseases & Belia- 
ghata General Hospital
B C Roy Memorial Hospital for 
Children
Number of beds 560 250
Admission/day 67 24
Occupancy rate 34% 75%
Average length (days) of stay  2.89 7.98
Total hospital cost (acquisition) 1,356,843 1,335,569
Cost per outpatient visit (US$*) 0.37 0.69
Cost per inpatient day (US$*) 15.27 10.80
*Based on 2004 prices; US$ 1=Indian Rs 44
Age-group No. %
Age (years) Length (days) of stay 
Mean SD Mean SD
Children
Hospitalized 10 13.0 7.90 4.01 8.40 2.07
Outpatients 67 87.0 5.90 3.02 NA NA
Both types   77 100.0 6.16 3.21 NA NA
Adults
Hospitalized 6 100.0 22.67 6.28 4.17 2.93
Outpatients 0 0.0 NA NA NA NA
Both types   6 100.0 22.67 6.28 NA NA
All ages
Hospitalized 16 19.3 13.44 8.79 6.81 3.15
Outpatients 67 80.7 5.90 3.02 NA NA
Both types   83 100.0 7.35 5.52 NA NA
 NA=Not applicable; SD=Standard deviation
Most included patients were children (77 of 83 cas-
es, 93%) and outpatients (81%). There were no adult 
outpatients. The average age was 6.16 years and 
22.67 years for children and adults respectively. The 
average length of stay at the hospital was 6.81 days. 
Child inpatients stayed longer than adult patients 
(8.40 vs 4.17 days). Details are presented in Table 2.  
Table 3 shows composition of treatment cost. It 
was found that pharmacy cost (acquisition drug 
cost and dispensing-service cost) was approximate-
Category






Laboratory cost 83.33 4.83 83.33 -
Pharmacy cost 242.64 14.08 242.64 -
Routine service cost 1,397.67 81.09 1,011.27 27.65
Total treatment cost 1,723.64 100 1,337.24 22.42
*US$ 1=Indian Rs 44 Sur D et al. Treatment cost for typhoid fever
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ly 15% of the treatment cost. The major part of 
the cost (approximately 80%) was routine-service 
cost, particularly that for the hospitalization. It was 
also found that if the number of inpatient days in-
creased to result in 80% occupancy rate, the cost 
decreased by nearly one-fourth.
The average treatment costs are presented in Table 
4. For base case, the average treatment cost of ty-
phoid patients was US$ 20.77. However, there was 
a substantial difference between outpatient and in-
patient costs (US$ 2 vs US$ 99.36). The average cost 
of hospitalized child patient was US$ 115.36. This 
Age-group
Base case 80% occupancy rate 
Mean SD Mean SD
Children
Hospitalized (n=10, 13%)
Laboratory 8.33 17.45 8.33 17.45
Pharmacy 10.08 11.31 10.08 11.31
Routine service 96.94 22.07 80.06 26.30
Total 115.36 28.67 98.48 34.25
Outpatients (n=67, 87%)
Laboratory 0* NA 0* NA
Pharmacy 1.30 1.11 1.30 1.11
Routine service 0.69* NA 0.69* NA
Total 2.00 1.11 2.00 1.11
Both types (n=77, 100%)
Laboratory 1.08 6.63 1.08 6.63
Pharmacy 2.44 5.00 2.44 5.00
Routine service 13.19 33.44 11.00 28.34
Total 16.72 39.62 14.53 34.72
Adults
Hospitalized (6, 100%)
Laboratory 0* NA 0* NA
Pharmacy 9.09 9.72 9.09 9.72
Routine service 63.62 44.69 27.35 19.21
Total 72.71 53.05 36.44 27.83
All ages
Hospitalized (n=16, 19.3%)
Laboratory 5.21 14.14 5.21 14.14
Pharmacy 9.71 10.42 9.71 10.42
Routine service 84.44 35.15 60.30 35.11
Total 99.36 43.43 75.22 43.87
Outpatients (n=67, 80.7%)
Laboratory 0* NA 0* NA
Pharmacy 1.30 1.11 1.30 1.11
Routine service 0.69* NA 0.69* NA
Total 2.00 1.11 2.00 1.11
Both types (n=83, 100%)
Laboratory 1.00 6.39 1.00 6.39
Pharmacy 2.92 5.65 2.92 5.65
Routine service 16.83 36.48 12.18 28.02
Total 20.77 42.89 16.11 34.60
*Constant; †Routine service cost consisting of cost of outpatient service (consultation cost) and inpatient 
service (hotel cost); ‡Routine service cost of outpatient was equal (or constant) for all outpatients. In ad-
dition, all outpatients did not have laboratory cost; NA=Not applicable; SD=Standard deviationSur D et al. Treatment cost for typhoid fever
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was much higher than that of the adult patients 
(US$ 72.71). These treatment costs were presented 
for both base case and simulated scenario at 80% 
inpatient bed-occupancy rate.  
DISCUSSION
Treatment cost for this study was obtained by 
multiplying the unit costs of medical services and 
quantity of the services used. The two hospitals in-
cluded in this study were quite different in terms 
of capacity-use, and this was illustrated by a huge 
difference in the occupancy rates. Hence, treat-
ment costs based on actual situation (base case) 
might have limitation for generalization. To over-
come this limitation, re-analysis of the treatment-
cost by employing 80% of capacity-use in terms of 
occupancy rate (following the recommendation of 
WHO) was done (17). Hence, the results obtained 
by using 80% occupancy rate should be used for 
planning at the national level. 
While comparing the treatment cost between age-
groups, it was found that the hospitalized child pa-
tients had higher cost than that of the hospitalized 
adult patients. This was because the length of stay of 
child patients was double compared to adults. As 
routine service cost (at outpatient and inpatient de-
partments) contributed 81% of the total cost, a lon-
ger duration of stay of the child patients led to higher 
treatment cost for them compared to the adults.
A study in the urban slums of Delhi in 1996 found 
that the average direct cost of blood culture-con-
firmed typhoid, blood culture-confirmed paraty-
phoid, and clinical typhoid was Rs 277, Rs 74, and 
Rs 432 respectively (3). These costs were converted 
into US dollar in 2004 rate, and the same stood at 
US$ 12.14, 7.63, and 18.94 respectively (18). The 
present study also calculated the average treat-
ment cost of blood culture-confirmed typhoid, 
blood culture-confirmed paratyphoid, and Widal 
test-positive cases. However, the sample size of 
the subgroups was too small to present the means 
separately. Hence, the average treatment cost was 
reported, and it was US$ 16.11, which was quite 
similar to the average treatment cost found in the 
study in Delhi.
The present study has some limitations. First, real 
prices of drugs purchased by the hospital or gov-
ernment pharmaceutical agency were not avail-
able. Drug-prices quoted from Drug Today were 
the quoted prices of pharmaceutical companies. 
We had no information of whether those prices 
were higher or lower than those purchased by the 
hospital. Second, information on capital assets, e.g. 
equipment, were not available for calculation of 
the capital cost. The estimation of 15% of the total 
cost for capital cost was based on Thailand experi-
ence. Furthermore, there were no adult outpatients 
in this study, and the sample size for adult hospital-
ized cases was also very small. To estimate more ac-
curate average treatment cost for typhoid, weighted 
average should be applied. This was not possible in 
this study due to paucity of data on estimated 
treatment cost of adult outpatients and proportion 
of patients (child vs adult) receiving treatment at 
outpatient and inpatient departments.  
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